Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Saliva as a noninvasive diagnostic for ocular sarcoidosis.

Journal of leukocyte biology·2026
Same author

Oral cyclophosphamide as part of the treatment regimen in patients with nonparaneoplastic autoimmune retinopathy secondary to birdshot chorioretinopathy.

Oman journal of ophthalmology·2026
Same author

How to interpret low-dose valacyclovir for postherpetic neuralgia in the Zoster Eye Disease Study-a randomized clinical trial.

Annals of translational medicine·2026
Same author

Oral cyclophosphamide monotherapy in advanced resistant ocular cicatricial pemphigoid.

Taiwan journal of ophthalmology·2025
Same author

The Rate of Failure of Trabeculectomy and Tube Shunt Surgery in Eyes with Uveitic Glaucoma and Ocular Hypertension.

Ophthalmology. Glaucoma·2025
Same author

Effectiveness of Frequently Used TNF Inhibitors vs. Conventional Immunosuppressive Therapies for Noninfectious Uveitis.

Ocular immunology and inflammation·2025

Related Experiment Video

Updated: May 18, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Antiphospholipid antibody syndrome.

Paul Yang1, Jonathan N Kruh, C Stephen Foster

  • 1Massachusetts Eye Research and Surgery Institution, Ocular Immunology and Uveitis Foundation, Cambridge, Massachusetts, USA.

Current Opinion in Ophthalmology
|October 9, 2012
PubMed
Summary

Antiphospholipid syndrome, a rare cause of eye vaso-occlusive disease, requires early diagnosis and treatment due to severe systemic risks. Recent advancements improve understanding and management of this condition.

More Related Videos

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)

Published on: October 7, 2009

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Related Experiment Videos

Last Updated: May 18, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)

Published on: October 7, 2009

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Background:

  • Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent thrombotic events and pregnancy complications.
  • It can manifest as ocular vaso-occlusive disease, a rare but serious complication associated with significant systemic morbidity and mortality.
  • Early diagnosis and prompt treatment are crucial for managing APS and preventing severe outcomes.

Purpose of the Study:

  • To review the current understanding of antiphospholipid syndrome (APS) as a cause of ocular vaso-occlusive disease.
  • To highlight recent advancements in the pathophysiology, diagnosis, and management of APS.
  • To emphasize the importance of early detection and intervention in patients with APS.

Main Methods:

  • Literature review focusing on antiphospholipid syndrome and ocular manifestations.
  • Analysis of recent findings regarding antiphospholipid antibodies and their targets.
  • Inclusion of updated guidelines from the 13th International Committee on Antiphospholipid Antibodies.

Main Results:

  • While the exact pathophysiology of APS remains under investigation, progress has been made in understanding the link between antiphospholipid antibodies and β-2-glycoprotein I.
  • Limitations in standard serologic evaluations are prompting the exploration of novel diagnostic approaches.
  • New guidelines for the management of APS have been established, offering updated treatment strategies.

Conclusions:

  • Enhanced understanding of APS pathophysiology is driving innovative diagnostic and therapeutic strategies.
  • The review underscores the critical need for timely diagnosis and management of APS to mitigate systemic and ocular complications.
  • Continued research into APS pathogenesis and diagnostic methods is essential for improving patient outcomes.